ZA894380B - Essential fatty acid compositions - Google Patents

Essential fatty acid compositions

Info

Publication number
ZA894380B
ZA894380B ZA894380A ZA894380A ZA894380B ZA 894380 B ZA894380 B ZA 894380B ZA 894380 A ZA894380 A ZA 894380A ZA 894380 A ZA894380 A ZA 894380A ZA 894380 B ZA894380 B ZA 894380B
Authority
ZA
South Africa
Prior art keywords
fatty acid
essential fatty
acid compositions
acid selected
series acids
Prior art date
Application number
ZA894380A
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Efamol Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings filed Critical Efamol Holdings
Publication of ZA894380B publication Critical patent/ZA894380B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA894380A 1988-06-10 1989-06-09 Essential fatty acid compositions ZA894380B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888813766A GB8813766D0 (en) 1988-06-10 1988-06-10 Essential fatty acid compositions

Publications (1)

Publication Number Publication Date
ZA894380B true ZA894380B (en) 1990-02-28

Family

ID=10638418

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA894380A ZA894380B (en) 1988-06-10 1989-06-09 Essential fatty acid compositions

Country Status (13)

Country Link
US (2) US4977187A (xx)
EP (2) EP0454102A3 (xx)
JP (1) JP2796838B2 (xx)
KR (1) KR0129666B1 (xx)
AT (1) ATE87825T1 (xx)
AU (2) AU618814B2 (xx)
CA (1) CA1334004C (xx)
DE (1) DE68905863T2 (xx)
ES (1) ES2053990T3 (xx)
GB (1) GB8813766D0 (xx)
IE (1) IE63303B1 (xx)
NZ (1) NZ229423A (xx)
ZA (1) ZA894380B (xx)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US6103755A (en) * 1990-05-22 2000-08-15 Bumann; Harold Foodstuff with prophylactic and/or healing effect and process for its production
EP0457950B1 (fr) * 1990-05-23 1993-10-20 Societe Des Produits Nestle S.A. Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
BR9205526A (pt) * 1991-01-24 1994-04-19 Martek Corp Sociedade Norte Am Misturas de oleos microbianos e usos dos mesmos
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
FR2679109B1 (fr) * 1991-07-18 1994-03-11 Institut Recherche Biologique Sa Nouveaux complements nutritionnels ou dietetiques anti-vieillissement a base d'acide gras poly-insature.
JPH07114761B2 (ja) * 1991-08-29 1995-12-13 ジェクス株式会社 皮膚清拭用品
US5436269A (en) * 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
CA2123678A1 (en) * 1991-11-26 1993-06-10 Alain Martin Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
ATE264099T1 (de) * 1993-06-09 2004-04-15 Martek Biosciences Corp Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
WO1995035273A1 (fr) * 1994-06-22 1995-12-28 Asahi Kasei Kogyo Kabushiki Kaisha Procede de production de methacroleine
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0928185B1 (en) * 1996-06-03 2003-09-03 CRODA INTERNATIONAL plc Compositions and uses thereof
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
PT956013E (pt) * 1996-10-11 2003-08-29 Scarista Ltd Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
GB9724783D0 (en) * 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
JP2004527501A (ja) 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
AU2002318135B2 (en) * 2001-05-14 2007-08-02 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
WO2002092540A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
EP1450787A4 (en) * 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS
FR2833174B1 (fr) * 2001-12-06 2004-05-28 Margaret Bronnert Pommade grasse d'origine animale destinee a soulager des demangeaisons et irritations de la peau dues aux dermites, eczema atopique et psoriasis,secheresse cutanee et hyperkeratinose
CN101072509A (zh) 2002-03-08 2007-11-14 孟山都技术有限公司 炎症的治疗和预防
JP2005532394A (ja) * 2002-07-02 2005-10-27 ガリレオ ファーマシューティカルズ， インコーポレイティド 雌性被験体における炎症性症状および／またはバイオマーカーの低減のための組成物および方法
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
AU2003255863A1 (en) * 2002-07-31 2004-02-23 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
MXPA06002028A (es) 2003-08-21 2006-05-17 Monsanto Technology Llc Desaturasas de acido graso de primula.
EP1711173A2 (en) * 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
CA2551882A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
CZ2006628A3 (cs) * 2004-03-12 2007-01-24 Egis Gyogyszergyár Nyrt. Kombinovaná farmaceutická kompozice pro inhibici poklesu kognitivních funkcí
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
CA2562548C (en) 2004-04-16 2019-08-20 Monsanto Technology Llc Expression of fatty acid desaturases in corn
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물
BRPI0517095B1 (pt) 2004-11-04 2018-05-29 Monsanto Technology Llc Processo para preparação de uma composição de óleo
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
WO2007106728A2 (en) 2006-03-10 2007-09-20 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010028419A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9480271B2 (en) 2009-09-15 2016-11-01 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
EP2708230A4 (en) * 2011-05-12 2014-12-03 Nippon Suisan Kaisha Ltd COMPOSITION FOR APPEARANCE ON THE SKIN FOR INFLAMMATORY DISEASES
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
AU2014358145C1 (en) 2013-12-04 2022-09-15 Nippon Suisan Kaisha, Ltd. Microbial oil, production method for microbial oil, concentrated microbial oil, and production method for concentrated microbial oil
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US20230059473A1 (en) * 2021-08-09 2023-02-23 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) * 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Also Published As

Publication number Publication date
ES2053990T3 (es) 1994-08-01
NZ229423A (en) 1992-10-28
IE891819L (en) 1989-12-10
AU7943491A (en) 1991-09-12
ATE87825T1 (de) 1993-04-15
AU633442B2 (en) 1993-01-28
CA1334004C (en) 1995-01-17
GB8813766D0 (en) 1988-07-13
JPH0232017A (ja) 1990-02-01
DE68905863D1 (de) 1993-05-13
EP0347056B1 (en) 1993-04-07
KR0129666B1 (ko) 1998-04-09
EP0454102A2 (en) 1991-10-30
US4977187A (en) 1990-12-11
EP0347056A1 (en) 1989-12-20
DE68905863T2 (de) 1993-08-26
IE63303B1 (en) 1995-04-05
US5120760A (en) 1992-06-09
AU618814B2 (en) 1992-01-09
JP2796838B2 (ja) 1998-09-10
EP0454102A3 (en) 1992-01-02
AU3597489A (en) 1989-12-14
KR900000078A (ko) 1990-01-30

Similar Documents

Publication Publication Date Title
EP0454102A3 (en) Essential fatty acid compositions
IL129367A0 (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
AU586892B2 (en) Pharmaceutical and dietary composition
HUT52341A (en) Method for producing preparations
ES2060290T3 (es) Composiciones de acidos grasos esenciales (efa) y terapia.
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
MY110734A (en) Improvements in or relating to dioic acids.
MY112705A (en) Tryglycerides
DE3570362D1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
TW336171B (en) Pharmaceutical composition for use in the treatment of vulvar dystrophy and/or vaginal dryness
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
AU6843000A (en) High lipid diet
AU7018187A (en) Iron - containing composition and method for treatment of cancer
IE842424L (en) Topical preparations containing tar and fatty acids
IL70128A (en) 3,7-dimethyl-9-(3-alkyl-4-trifluoromethoxy-phenyl)-nona-2,4,6,8-tetraenoic acid derivatives,their manufacture and pharmaceutical compositions containing them
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
EP0155015A3 (en) Less-irritant hair-rinse composition